Compass Financial Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-4,633
Closed -$384K 32
2023
Q1
$384K Buy
4,633
+1,372
+42% +$114K 0.49% 70
2022
Q4
$280K Sell
3,261
-240
-7% -$19K 0.38% 92
2022
Q3
$216K Hold
3,501
0.32% 104
2022
Q2
$216K Sell
3,501
-381
-10% -$23.6K 0.29% 113
2022
Q1
$231K Buy
3,882
+403
+12% +$25.8K 0.26% 122
2021
Q4
$253K Buy
+3,479
New +$240K 0.28% 112

Other funds holding GILD

Compass Financial Advisors's GILD Position: Q2 2023 in Review

Compass Financial Advisors sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 4,633 shares — an estimated $384K sold.

Compass Financial Advisors first reported a position in GILD in Q4 2021 and held it in 6 quarters. The position peaked at $384K in Q1 2023. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

  • Compass Financial Advisors reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
  • Compass Financial Advisors sold 4,633 Gilead Sciences shares in Q2 2023, an estimated $384K.
  • Compass Financial Advisors first reported a position in Gilead Sciences in Q4 2021 and held it in 6 quarters.
  • Compass Financial Advisors's Gilead Sciences position peaked at $384K in Q1 2023.
  • 1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Compass Financial Advisors's 13F filing for Q2 2023.